These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 2700533)

  • 21. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma.
    Musolino C; Allegra A; Orlando A; Grosso P; Alonci A; Cincotta M; Squadrito G
    Riv Eur Sci Med Farmacol; 1990; 12(4-5):233-8. PubMed ID: 2103961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Total soluble HLA class I and soluble HLA-G in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Leleu X; Le Friec G; Facon T; Amiot L; Fauchet R; Hennache B; Coiteux V; Yakoub-Agha I; Dubucquoi S; Avet-Loiseau H; Mathiot C; Bataille R; Mary JY;
    Clin Cancer Res; 2005 Oct; 11(20):7297-303. PubMed ID: 16243800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A study of the significance of serum beta 2-microglobulin levels in patients with multiple myeloma--analyzes as a marker of renal dysfunction and as a marker of tumor cell mass].
    Nishinarita S; Shimada H; Suzuki R; Kishigami Y; Sawada U; Horie T
    Rinsho Ketsueki; 1996 Mar; 37(3):201-7. PubMed ID: 8727343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Beta-2-microglobulin in multiple myeloma.
    Musarurwa C; Matarira HT
    Cent Afr J Med; 2004; 50(1-2):19-20. PubMed ID: 15490720
    [No Abstract]   [Full Text] [Related]  

  • 27. [Beta 2 microglobulin in some hematologic neoplasms].
    Rodríguez MA; Lira P; Foradori A; Grebe G
    Rev Med Chil; 1989 Jun; 116(6):538-42. PubMed ID: 2664940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
    Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum beta 2-microglobulin at remission and relapse in patients with multiple myeloma.
    Brenning G; Wibell L; Bergström R
    Eur J Clin Invest; 1985 Oct; 15(5):242-7. PubMed ID: 3935453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relation between clinical stage of sarcoidosis and serum values of angiotensin converting enzyme and beta2-microglobulin.
    Selroos O; Klockars M
    Sarcoidosis; 1987 Mar; 4(1):13-7. PubMed ID: 3035674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and clinical studies of serum beta 2-microglobulin levels in haematological malignancies.
    Nakao Y; Matsumoto H; Miyazaki T; Watanabe S; Masaoka T; Takatsuki K; Kishihara M; Kobayashi N; Hattori M; Fujita T
    Clin Exp Immunol; 1981 Oct; 46(1):134-41. PubMed ID: 6175458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-2-microglobulin (beta 2M) as a tumor marker in nasopharyngeal carcinoma.
    Lee JK; Tsai SC; Hsieh JF; Ho YJ; Sun SS; Kao CH
    Anticancer Res; 2000; 20(6C):4765-8. PubMed ID: 11205215
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma.
    Rajkumar SV; Fonseca R; Lacy MQ; Witzig TE; Lust JA; Greipp PR; Therneau TM; Kyle RA; Litzow MR; Gertz MA
    Bone Marrow Transplant; 1999 Jun; 23(12):1261-6. PubMed ID: 10414913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of serum neural cell adhesion molecule as a prognostic marker in multiple myeloma.
    Poley S; Stieber P; Nüssler V; Pahl H; Fateh-Moghadam A
    Anticancer Res; 1997; 17(4B):3021-4. PubMed ID: 9329591
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment serum beta 2-microglobulin in multiple myeloma.
    Brenning G; Simonsson B; Källander C; Ahre A
    Br J Haematol; 1986 Jan; 62(1):85-93. PubMed ID: 3510657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
    Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
    Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Beta 2 microglobulin in serum--a "tumor marker" in malignant lymphomas?].
    Aulbert E; Steffens O
    Med Klin (Munich); 1990 Jan; 85(1):13-7. PubMed ID: 2179698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple myeloma with 5-year survival. Study of initial prognostic factors. Role of beta-2-microglobulin].
    Franco M; Fuzibet JG; Cassuto JP; Pesce A; Ziegler G; Dujardin P
    Rev Rhum Mal Osteoartic; 1985 Nov; 52(11):619-23. PubMed ID: 3909365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unexpected normal serum beta-microglobulin (B2M) levels in multiple myeloma.
    Bataille R; Grenier J; Sany J
    Anticancer Res; 1987; 7(3 Pt B):513-5. PubMed ID: 3307602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.